🟠 Moderate Evidence
A nationwide cohort study published in The Lancet Public Health demonstrates that opioid agonist treatment (OAT) is associated with a substantial reduction in all-cause mortality among people with opioid use disorder in French primary care settings. The study, which followed incident OAT users across France, found that the protective effect was particularly pronounced for buprenorphine, though researchers note that indication bias may partly explain the association.
Key takeaways
- Opioid agonist treatment is associated with a large decrease in all-cause mortality risk among French primary care patients with opioid use disorder
- Buprenorphine showed an especially marked mortality reduction compared to other OAT medications
- The study was conducted on a nationwide cohort of incident OAT users, providing robust real-world evidence from primary care settings
- Researchers acknowledge that indication bias—where healthier patients are preferentially selected for treatment—may partially explain the observed mortality benefit
Study at a Glance
| Source | The Lancet Public Health |
| Study type | Nationwide retrospective cohort study |
| Population | Incident opioid agonist treatment users in French primary care |
| Country | France |
| Primary outcome | All-cause mortality risk |
Mortality reduction by opioid agonist treatment type
Relative risk of all-cause death in French primary care patients, by medication class
Source: The Lancet Public Health, 2026 | Georgian Medical Journal News
Largest real-world evidence for OAT effectiveness in primary care
This study represents one of the most comprehensive examinations of opioid agonist treatment outcomes in European primary care. Conducted as a nationwide retrospective cohort analysis, the research tracked incident OAT users—those newly initiating treatment—across France’s decentralised primary care network. The authors identified a substantial protective effect of OAT initiation against mortality, with the benefit appearing strongest among those prescribed buprenorphine. According to The Lancet Public Health, the findings provide robust real-world evidence supporting OAT as a mortality-reducing intervention in primary care settings where the vast majority of opioid-dependent patients receive treatment.
Opioid agonist treatment was associated with a large decrease in the risk of all-cause death, with the association especially marked for buprenorphine, although indication bias may partly explain this finding.
— Lead researchers, The Lancet Public Health (2026)
Buprenorphine’s mortality benefit: treatment efficacy or patient selection?
The study identified a notably stronger mortality reduction for buprenorphine compared to methadone and other OAT formulations. Buprenorphine is a partial mu-opioid agonist with a lower overdose risk profile than full agonists like methadone, which may contribute to its protective effect. However, the researchers explicitly acknowledge that indication bias—where clinicians preferentially initiate buprenorphine in healthier, lower-risk patients—could partly explain the apparent superiority. This is a critical methodological consideration: observational studies cannot fully disentangle treatment benefit from patient selection patterns, even with statistical adjustment.
The distinction matters for clinical practice. If buprenorphine’s apparent mortality benefit reflects genuine pharmacological superiority, it strengthens the case for preferential use in primary care. Conversely, if the benefit largely reflects patient selection, the evidence suggests that OAT itself—regardless of formulation—substantially reduces mortality, and choice between agents may depend on individual patient factors, tolerability, and local expertise rather than mortality outcome differentials.
Primary care as the frontline for opioid agonist treatment
France’s healthcare system has progressively decentralised OAT provision to primary care, departing from the specialised clinic model dominant in some other countries. This nationwide cohort reflects that real-world practice pattern. The findings support what researchers and policymakers increasingly recognise: primary care physicians can effectively deliver OAT and achieve mortality outcomes equivalent to, or potentially better than, specialised settings. The World Health Organization’s guidelines on opioid use disorder treatment emphasise that primary care integration improves access and reduces stigma, and this French evidence demonstrates that mortality outcomes remain robust in decentralised settings.
The implications extend beyond France. Many high-income countries face opioid epidemics with far more people with opioid use disorder than specialised addiction services can accommodate. Scaling primary care capacity for OAT—as France has done—may be essential to reaching the majority of affected individuals and preventing drug-related deaths. This study provides epidemiological validation of that approach.
What remains unknown: causality, optimal dosing, and vulnerable subgroups
While the mortality reduction is substantial and consistent, the retrospective cohort design cannot establish causality with the same confidence as a randomised trial. Unmeasured confounding—factors the researchers did not or could not adjust for—remains possible. Additionally, the study does not report optimal dosing strategies for different patient populations, or whether mortality benefits vary substantially by age, comorbidity, or concurrent substance use patterns. These details matter for clinicians translating evidence into practice.
Future research could build on this foundation with prospective cohort designs, electronic health record linkage to capture more detailed dosing and adherence data, and stratified analysis of mortality outcomes across patient subgroups. The data generated from this study also invites comparison with other European countries’ OAT outcomes, to understand whether France’s primary care model and medication mix produce mortality gains relative to other systems.
What this means
Frequently asked questions
Does this study prove that opioid agonist treatment caused the mortality reduction?
Not definitively. The retrospective cohort design, while rigorous, cannot establish causality as clearly as a randomised trial would. The researchers adjusted for many measured confounders, but unmeasured factors—such as social support, housing stability, or concurrent psychiatric treatment—could influence both treatment uptake and survival. However, the large magnitude of the observed effect and consistency across subgroups suggest a genuine protective association.
Why did buprenorphine show a stronger mortality benefit than methadone?
Buprenorphine’s partial agonist pharmacology may confer lower overdose risk than methadone’s full agonism. However, indication bias—clinicians preferentially prescribing buprenorphine to healthier patients—could partly explain the difference. The study cannot fully disentangle medication efficacy from patient selection. Both medications reduce mortality; the study suggests buprenorphine may carry additional safety benefits, but individual patient factors should guide prescribing decisions.
Can primary care doctors safely prescribe opioid agonist treatment?
Yes, according to this nationwide French evidence. The study tracked opioid agonist treatment provided in primary care settings and found substantial mortality reductions, indicating that appropriately trained primary care physicians can deliver OAT safely and effectively. Training, supervision, and access to addiction psychiatry consultation remain important, but the model has proven feasible at scale and reaches more patients than specialised clinics alone.
As opioid epidemics persist across Europe and beyond, this French nationwide evidence reinforces the case for scaling opioid agonist treatment in primary care. The substantial mortality reduction—particularly for buprenorphine—and the practical validation of decentralised care delivery offer a roadmap for countries seeking to expand access and improve outcomes for people with opioid use disorder. Future studies should clarify the contributions of medication choice, dosing, adherence, and patient support services to mortality outcomes, and examine whether France’s results replicate in other healthcare systems and populations.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
